Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +55

Elevation Point Wealth Partners LLC Acquires 64,908 Shares of Boston ...

AI-generated analysis

πŸ“ˆ Elevation Point Wealth Partners LLC raised its stake by 429.8% in Q1, adding 64,908 shares to a total holding of 80,011 shares valued at $5.02 million.

🏦 Several other institutions including FWL Investment Management LLC and Swiss RE Ltd. established new positions worth approximately $26,000 each.

πŸ’Ό Director Cheryl Pegus purchased 1,770 shares for $99,987.30, while Director David C. Habiger acquired 2,250 shares for $125,820 on May 20th.

πŸ“Š Insiders collectively bought 9,800 shares valued at $554,012 over the last three months, representing a net increase in their holdings.

πŸ’° The company reported Q1 revenue of $5.20 billion, an 11.6% year-over-year increase that beat analyst estimates by $10 million.

πŸ“‰ Earnings per share reached $0.80, surpassing the consensus estimate of $0.79 with a net margin of 17.29% and ROE of 19.17%.

πŸš€ Management raised Q2 2026 EPS guidance to a range of $0.82-$0.84 and set full-year 2026 EPS guidance between $3.34-$3.41.

πŸ”„ The board authorized a new $5 billion share repurchase program, permitting the buyback of up to 6.4% of outstanding shares.

πŸ“‰ Wolfe Research downgraded the stock from 'outperform' to 'peer perform', while Barclays lowered its price target from $96.00 to $89.00.

πŸ“ˆ Conversely, Needham & Company restated a 'buy' rating with a $77.00 target, and BTIG Research maintained a 'buy' with a $65.00 objective.

🎯 The consensus analyst rating is 'Moderate Buy' with an average price target of $83.36 based on MarketBeat data.

πŸ₯ Boston Scientific focuses on less-invasive medical procedures for cardiovascular, digestive, urologic, pulmonary, and chronic pain conditions.

Bullish Signals
  • Elevation Point Wealth Partners LLC significantly increased its position by 429.8% in Q1, adding 64,908 shares to a total holding of 80,011 shares valued at $5.02 million.
  • Company insiders purchased 9,800 shares worth over $554,000 in the last three months, signaling confidence in the stock's near-term prospects.
  • Q1 revenue of $5.20 billion exceeded analyst estimates by $10 million and grew 11.6% year-over-year, demonstrating strong top-line growth.
  • The company beat Q1 EPS expectations with a result of $0.80 versus the consensus of $0.79, indicating operational efficiency.
  • Management raised full-year 2026 EPS guidance to a range of $3.34-$3.41, suggesting confidence in future performance.
  • The board authorized a substantial $5 billion stock repurchase program, allowing the buyback of up to 6.4% of outstanding shares.
  • Analysts maintain a 'Moderate Buy' consensus rating with an average price target of $83.36, reflecting overall market confidence.
Risk Factors
  • Wolfe Research downgraded the stock from 'outperform' to 'peer perform', indicating a reduction in growth expectations relative to peers.
  • Barclays decreased its price target from $96.00 to $89.00, suggesting a more conservative valuation outlook for the company.
  • Wall Street Zen lowered its rating from 'buy' to 'hold', reflecting mixed sentiment among some analysts regarding current valuations.
Full Analysis
Elevation Point Wealth Partners LLC significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 429.8% in the first quarter, adding 64,908 shares to reach a total holding of 80,011 shares valued at $5.02 million. Other institutional investors also adjusted positions, with FWL Investment Management LLC, Swiss RE Ltd., and Garton & Associates Financial Advisors LLC establishing new positions worth approximately $26,000 each in the second or fourth quarters. Company insiders demonstrated bullish sentiment through recent purchases. Director Cheryl Pegus acquired 1,770 shares for roughly $100,000, while Director David C. Habiger bought 2,250 shares for about $126,000, increasing his personal stake by 19.35%. Collectively, insiders purchased 9,800 shares valued at over $554,000 in the last three months, though they still hold only 0.34% of the company's total stock. Financially, Boston Scientific reported strong quarterly results with revenue of $5.20 billion, beating estimates by $10 million and growing 11.6% year-over-year. The company posted earnings per share (EPS) of $0.80 versus a consensus of $0.79, achieving a net margin of 17.29%. Management provided guidance for Q2 2026 EPS between $0.82 and $0.84, with full-year 2026 EPS expectations ranging from $3.34 to $3.41. The company announced a new $5 billion stock repurchase program authorized by its board on May 18th, allowing the reacquisition of up to 6.4% of outstanding shares. Analyst sentiment remains mixed but generally positive, with a consensus rating of 'Moderate Buy' and a target price of $83.36, despite recent downgrades from Wolfe Research and Wall Street Zen.